Quoin Pharmaceuticals Ltd. Finance Costs
Quoin Pharmaceuticals Ltd. (QNRX) reported Finance Costs of ILS 4.08 million for the 12-month period ending 2020-12-31, per its 20-F filed 2021-03-29.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:FinanceCosts · last filed 2021-03-29
ILS
| Period end | Finance Costs 0 month | Finance Costs 6 month | Finance Costs 12 month |
|---|---|---|---|
| 2020-12-31 | 4.08M ILS 20-F · filed 2021-03-29 | ||
| 2020-06-30 | 3.85M ILS 6-K/A · filed 2021-02-11 | ||
| 2019-12-31 | 1.47M ILS 20-F · filed 2021-03-29 | ||
| 2019-06-30 | 880.00K ILS 6-K/A · filed 2021-02-11 | ||
| 2018-12-31 | 20.00K ILS 20-F · filed 2021-03-29 | ||
| 2018-06-30 | 12.00K ILS 6-K · filed 2019-08-13 | ||
| 2017-12-31 | 3.89M ILS 20-F · filed 2020-04-03 | ||
| 2017-06-30 | 5.82M ILS 6-K · filed 2018-08-09 | ||
| 2016-12-31 | 33.00K ILS 20-F · filed 2019-03-18 | ||
| 2016-07-28 | -622.00K ILS 20-F · filed 2018-03-19 | ||
| 2015-12-31 | 79.00K ILS 20-F · filed 2018-03-19 |
USD
| Period end | Finance Costs 6 month | Finance Costs 12 month |
|---|---|---|
| 2020-12-31 | $1.27M 20-F · filed 2021-03-29 | |
| 2019-12-31 | $425.00K 20-F · filed 2020-04-03 | |
| 2018-06-30 | $3.00K 6-K · filed 2018-08-09 | |
| 2017-12-31 | $1.12M 20-F · filed 2018-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |